Member Info for Cheapsharesboy

Will it get there by March 2026?

Also needed to change that misleading title

Spread has narrowed too so MMs want to get this trading

It's all very good

Please see people here trying to get in on a lower price too

Although there is no guarantee it'll go lower

I suggest fill your boots now before it's too late

Guzzler MM doesn't know anything

Please stop talking rubbish

You're embarrassing

Dragon

This is a board where many people come and go with mo awareness of what has been done over the years.

Information and history surely helps rather than ignorance.

Or you invest in companies without understanding their history?

Ridiculous comment

Fusion raised 5.5M initially 2017 December on AIM listing

Here is a brief history from Fusion site:

The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.

The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.

Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.

The global monoclonal antibody therapeutics market was valued at $186 billion in 2021 and is forecast to surpass $445 billion in 2028, an increase at a CAGR of 13.2 per cent. for the period 2022 to 2028. Approximately 150 monoclonal antibody therapies are approved and marketed globally as of June 2022 with the top four antibody drugs each having sales of more than $3 bn in 2021.

I don't think that's true

It's more like waiting to se revenue increase and bigger contracts

The placing fears pretty much dissipated due to grant funding on December 4th

Yanks casually walk into office and buy 250K £ worth O trade. Cause why not?

It's cheap and won't be for long.

Well said Beo

Someone now selling at 6.6p! Sad to see

I agree Mole that Vod should preserve cash and/or pay back debt, not buyback shares

However your premise statement was incorrect, you said that "dying companies buy back shares"

That is FALSE.

APPLE IS THE BIGGEST COMPANY IN THE WORLD AND THEY Bought OVER £100B buyback. I just wanted to point out that your statement was completely and factually incorrect. Vodafone buying back shares DOES NOT IMPLY THAT THEY AR DYING.

Just like Apple buying back shares do not imply that.

Your statement was FALSE

Moleman "Divi buybacks are for dying companies"

Lol

Many leading American companies that are closer to trillions - buy back shares. Like APPLE.

Have you lost it completely Mole?

I know Tesla is not doing well for you but - I thought you are rational???

Now you talk the biggest shute I ever heard here!

It's probably worth noting that UK pharma is likely to be shielded from the tariffs. Furthermore, these tariffs would simply make a takeover bid more likely rather than the opposite. The reason for this is that if Fab tech is very valuable and if the cost of biotech and healthcare in general go up due to Trump tariffs and trade wars, it then becomes very likely that someone will want to take over Fusion Antibodies. They would want to make sure they have access to these products without the constant risk of higher costs, tariffs or lack to F supply altogether.

I think the "no supply" scenario is very likely for some biotech corporations in a world of trade wars. That would appear to increase the valuation for Fusion. Shares are available for peanuts so things could happen anytime. On top of that we got all the positive newsflow anticipated this year.

Full year results probably in 6 weeks time

We've had optimal update, new contract, and grant funding already. More to come, revenue more than doubled. It a difficult market but it'll pay off. Patience is the key now!

Very likely that Parameta will be listed in USA.

To Icap to retain majority holding. So potentially 30% proceeds 700M?

We would be in for a minimum of 50p per share dividend and a new share buyback programme, maybe worth 100-200M? Who knows.

As a result, we could be looking at £4 per share valuation here. Strong buy for me.

Filtered

No it's not laughable at all. You should grow up a bit and understand the world is made up of many opinions. Not just your leftist propaganda.

No I don't buy any cryptos.

Why do you care about what I buy? Please get a life for yourself instead.

I much rather buy these shares on such good results. And potential us listing.

I think you are the idiot

Trump is fighting your globalist corrupt politicians

Realistic nro

So this dead company has a new spammer.

It doesn't change anything

If QBT product was abysmal good, they would mine the bitcoin themselves. As it isn't, they won't do it!

Once people see the progress on full year update we should move further higher

Losses reduced and clear path to profitability and further updates/ contracts - there will be further buying when folks see the figures and progress.

Is the update end of April?

Lady year was April 30th

But whilst waiting further contracts are possible, there is a lot going on - sit back and wait.

Keyword studio got taken over from Aim.

Not all bad. The went from £10 to £24.50.

Same could happen here

I knows it's a difficult market but even Aim has winners and multibaggers. It's not all black and white. But yes it's a difficult market but with care it's still possible to pick out winners. Volume here dropped a lot so maybe the seller is done